Cargando…

MiR-33a functions as a tumor suppressor in triple-negative breast cancer by targeting EZH2

BACKGROUND: Increasing reports have confirmed that microRNAs play an important role in breast cancer progression, particularly in triple-negative breast cancer (TNBC). The aim of our study was to investigate the role of miR-33a in TNBC progression. METHODS: PCR assays were performed to detect miR-33...

Descripción completa

Detalles Bibliográficos
Autores principales: Weihua, Zeng, Guorong, Zou, Xiaolong, Cao, Weizhan, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7079399/
https://www.ncbi.nlm.nih.gov/pubmed/32206036
http://dx.doi.org/10.1186/s12935-020-1160-z
_version_ 1783507814504726528
author Weihua, Zeng
Guorong, Zou
Xiaolong, Cao
Weizhan, Li
author_facet Weihua, Zeng
Guorong, Zou
Xiaolong, Cao
Weizhan, Li
author_sort Weihua, Zeng
collection PubMed
description BACKGROUND: Increasing reports have confirmed that microRNAs play an important role in breast cancer progression, particularly in triple-negative breast cancer (TNBC). The aim of our study was to investigate the role of miR-33a in TNBC progression. METHODS: PCR assays were performed to detect miR-33a and EZH2 expression in TNBC tissues, adjacent nontumor tissues and cell lines. Western blot, CCK8, Transwell, cell colony formation and EdU cell proliferation, cell cycle analysis and luciferase reporter assays were used to determine the regulation of miR-33a/EZH2 in TNBC progression. RESULTS: MiR-33a was significantly downregulated in TNBC tissues and cell lines. MiR-33a overexpression in TNBC cells significantly inhibited cell growth and mobility and induced G1 cell cycle arrest. The luciferase reporter assay revealed that EZH2 is a direct target of miR-33a and that it was upregulated in TNBC tissues and cell lines. There was a negative correlation between miR-33a and EZH2 expression in TNBC tissues. EZH2 knockdown exerted similar inhibitory effects, while ectopic expression of EZH2 showed suppressive effects on malignant behaviors induced by miR-33a overexpression in TNBC cells. CONCLUSIONS: These findings revealed that miR-33a is a tumor-suppressive miRNA in TNBC and can inhibit proliferation and mobility and induce G1 cell cycle arrest by directly targeting EZH2.
format Online
Article
Text
id pubmed-7079399
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-70793992020-03-23 MiR-33a functions as a tumor suppressor in triple-negative breast cancer by targeting EZH2 Weihua, Zeng Guorong, Zou Xiaolong, Cao Weizhan, Li Cancer Cell Int Primary Research BACKGROUND: Increasing reports have confirmed that microRNAs play an important role in breast cancer progression, particularly in triple-negative breast cancer (TNBC). The aim of our study was to investigate the role of miR-33a in TNBC progression. METHODS: PCR assays were performed to detect miR-33a and EZH2 expression in TNBC tissues, adjacent nontumor tissues and cell lines. Western blot, CCK8, Transwell, cell colony formation and EdU cell proliferation, cell cycle analysis and luciferase reporter assays were used to determine the regulation of miR-33a/EZH2 in TNBC progression. RESULTS: MiR-33a was significantly downregulated in TNBC tissues and cell lines. MiR-33a overexpression in TNBC cells significantly inhibited cell growth and mobility and induced G1 cell cycle arrest. The luciferase reporter assay revealed that EZH2 is a direct target of miR-33a and that it was upregulated in TNBC tissues and cell lines. There was a negative correlation between miR-33a and EZH2 expression in TNBC tissues. EZH2 knockdown exerted similar inhibitory effects, while ectopic expression of EZH2 showed suppressive effects on malignant behaviors induced by miR-33a overexpression in TNBC cells. CONCLUSIONS: These findings revealed that miR-33a is a tumor-suppressive miRNA in TNBC and can inhibit proliferation and mobility and induce G1 cell cycle arrest by directly targeting EZH2. BioMed Central 2020-03-18 /pmc/articles/PMC7079399/ /pubmed/32206036 http://dx.doi.org/10.1186/s12935-020-1160-z Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Primary Research
Weihua, Zeng
Guorong, Zou
Xiaolong, Cao
Weizhan, Li
MiR-33a functions as a tumor suppressor in triple-negative breast cancer by targeting EZH2
title MiR-33a functions as a tumor suppressor in triple-negative breast cancer by targeting EZH2
title_full MiR-33a functions as a tumor suppressor in triple-negative breast cancer by targeting EZH2
title_fullStr MiR-33a functions as a tumor suppressor in triple-negative breast cancer by targeting EZH2
title_full_unstemmed MiR-33a functions as a tumor suppressor in triple-negative breast cancer by targeting EZH2
title_short MiR-33a functions as a tumor suppressor in triple-negative breast cancer by targeting EZH2
title_sort mir-33a functions as a tumor suppressor in triple-negative breast cancer by targeting ezh2
topic Primary Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7079399/
https://www.ncbi.nlm.nih.gov/pubmed/32206036
http://dx.doi.org/10.1186/s12935-020-1160-z
work_keys_str_mv AT weihuazeng mir33afunctionsasatumorsuppressorintriplenegativebreastcancerbytargetingezh2
AT guorongzou mir33afunctionsasatumorsuppressorintriplenegativebreastcancerbytargetingezh2
AT xiaolongcao mir33afunctionsasatumorsuppressorintriplenegativebreastcancerbytargetingezh2
AT weizhanli mir33afunctionsasatumorsuppressorintriplenegativebreastcancerbytargetingezh2